Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Priority Review Voucher Value Still Confounds, But Remains An Incentive For Sponsors

This article was originally published in The Pink Sheet Daily

Executive Summary

As FDA increases the asking price, a survey by non-profit finds companies would expect to invest an average of $100 million to obtain a voucher, but responders gave a wide range of potential amounts.

You may also be interested in...



Priority Review Weirdness: Tropical Voucher Sells For More; Owner Says It’s Worth Less

Knight Therapeutics says a rare pediatric disease voucher is more valuable than its tropical disease voucher despite the sale price.

Ebola Drugs Take Center Stage In Review Voucher Bill, But Real Value May Be Harmonization

Along with adding Ebola to list of disease treatments eligible for tropical disease priority review voucher, bill moving through Congress would cut notification time required before redemption.

Review Cost For Sanofi/Regeneron’s PCSK9 Inhibitor Remains Uncertain

Even after paying BioMarin $67.5 million for the voucher itself, the firms still don’t know how much FDA will charge for a chance to get Praluent to market faster.

Related Content

Topics

UsernamePublicRestriction

Register

PS072807

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel